{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:56:05Z","timestamp":1789448165012,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1118,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1093\/annonc\/mdw421","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:48:29Z","timestamp":1477356509000},"page":"2251-2257","source":"Crossref","is-referenced-by-count":49,"title":["Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation"],"prefix":"10.1016","volume":"27","author":[{"given":"S.","family":"Genadieva-Stavrik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Briones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Soci\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Velardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw421_bb0010","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw421_bb0015","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw421_bb0020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw421_bb0025","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high dose chemotherapy with autologous haematopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw421_bb0030","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/cncr.11414","volume":"97","author":"Tarella","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw421_bb0035","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Mart\u00ednez","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw421_bb0040","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdw421_bb0045","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw421_bb0050","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw421_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw421_bb0060","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus lymphoma effect after reduced intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw421_bb0065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin's lymphoma: results of a Spanish Prospective Cooperative Protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdw421_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw421_bb0075","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw421_bb0080","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdw421_bb0085","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of the conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdw421_bb0090","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw421_bb0095","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw421_bb0100","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw421_bb0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw421_bb0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013)","volume":"124","author":"Moskowitz","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw421_bb0115","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2008-11-189399","article-title":"Allogeneic hematopoetic stem cell transplantation in children and adolescent with recurrent and refractory Hodgkin lymphoma: analysis of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Claviez","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdw421_bb0120","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/leu.2012.318","article-title":"A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma","volume":"27","author":"Thomson","year":"2013","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdw421_bb0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbmt.2014.11.673","article-title":"Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation","volume":"21","author":"Truelove","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1093\/annonc\/mdw421_bb0130","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.2008.07349.x","article-title":"Allogeneic transplantation for Hodgkin lymphoma","volume":"143","author":"Peggs","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdw421_bb0135","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/12\/2251\/8623051\/mdw421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:44:46Z","timestamp":1718858686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0923753419365445"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw421","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}